Jefferies analyst David Steinberg projects an 18 month launch delay for Amphastar's over-the-counter asthma drug Primatene Mist HFA after the company received a second complete response letter ahead of the December 28 FDA action date. The analyst continues to view the product as approvable, noting that the original formulation of Primatene was available as an over-the-counter product for over 50 years. Steinberg lowered his FY17 revenue estimate for the company to $315.3M from $340.3M and FY18 estimate to $411.7M from $452.9M. He keeps a Buy rating on Amphastar with an $18 price target.